Free Trial
NASDAQ:CERO

CERo Therapeutics (CERO) Stock Price, News & Analysis

CERo Therapeutics logo
$0.08
0.00 (0.00%)
(As of 11/1/2024 ET)

About CERo Therapeutics Stock (NASDAQ:CERO)

Key Stats

Today's Range
$0.08
$0.09
50-Day Range
$0.08
$0.15
52-Week Range
$0.07
$12.80
Volume
1.07 million shs
Average Volume
4.50 million shs
Market Capitalization
$12.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Receive CERO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CERo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CERO Stock News Headlines

Cero Therapeutics submits IND clinical hold CRL to the FDA
Crypto Crash Ahead? (27 Experts Weigh In)
Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
CERo Therapeutics, Inc. Provides Corporate Update
CERo Therapeutics appoints new CFO and CDO
See More Headlines

CERO Stock Analysis - Frequently Asked Questions

CERo Therapeutics' stock was trading at $4.78 on January 1st, 2024. Since then, CERO shares have decreased by 98.3% and is now trading at $0.0831.
View the best growth stocks for 2024 here
.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.33) earnings per share (EPS) for the quarter.

Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Verve Therapeutics (VERV), Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI).

Company Calendar

Last Earnings
8/14/2024
Today
11/02/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CERO
Previous Symbol
NASDAQ:CERO
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-2,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($2.59) per share

Miscellaneous

Free Float
123,253,000
Market Cap
$12.49 million
Optionable
N/A
Beta
-0.50
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CERO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners